NovalGen announces one oral and one poster presentation at
NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting...
Source: globenewswire.com
Page 2 - Durable Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Durable Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Durable Response Today - Breaking & Trending Today
Day One Announces Updated FIREFLY-1 Data for Tovorafenib
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023,...
Source: globenewswire.com
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Overall response rate greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA...
Source: marketscreener.com
Gilead Sciences, Inc.: Kite's Tecartus CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
-- In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response (CR+CRi 71%) and a Median Overall Survival of 26 Months
Source: finanznachrichten.de
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to
- Cryopreserved, Post-thaw CAR T Cell Composition and Effective CAR T Cell Dose are Predictive for Response to Treatment with Azer-cel- Peak CAR T Expansion, a Key Determinant of Durable Response, Strongly Correlated with Effective CAR T DoseDURHAM, N.C.--(BUSINESS WIRE)--$DTIL #ARCUS--Precision BioSciences (Nasdaq:...
Source: pharmiweb.com